Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Bona Salinas, Eduardo"'
Autor:
Sisteré-Oró, Marta, Wortmann, Diana D. J., Andrade, Naína, Aguilar, Andres, Mayo de las Casas, Clara, Casabal, Florencia Garcia, Torres, Susana, Bona Salinas, Eduardo, Raventos Soler, Laura, Arcas, Andrea, Esparre, Carlos, Garcia, Beatriz, Valarezo, Joselyn, Rosell, Rafael, Güerri-Fernandez, Roberto, Gonzalez-Cao, Maria, Meyerhans, Andreas
Publikováno v:
Frontiers in Immunology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Cancer patients (CPs) have been identified as particularly vulnerable to SARS-CoV-2 infection, and therefore are a priority group for receiving COVID-19 vaccination. From the patients with advanced solid tumors, about 20% respond very efficiently to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49c3d853beb938167e2b80be5f763ba6
http://hdl.handle.net/10230/54049
http://hdl.handle.net/10230/54049
Autor:
Sisteré-Oró M; Infection Biology Laboratory, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain., Wortmann DDJ; Infection Biology Laboratory, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain., Andrade N; Infection Biology Laboratory, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain., Aguilar A; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain., Mayo de Las Casas C; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain.; Laboratorio Oncología, Hospital Universitario Dexeus, Pangaea Oncology Lab, Barcelona, Spain., Casabal FG; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain., Torres S; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain., Bona Salinas E; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain., Raventos Soler L; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain., Arcas A; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain., Esparre C; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain., Garcia B; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain.; Laboratorio Oncología, Hospital Universitario Dexeus, Pangaea Oncology Lab, Barcelona, Spain., Valarezo J; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain.; Laboratorio Oncología, Hospital Universitario Dexeus, Pangaea Oncology Lab, Barcelona, Spain., Rosell R; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain.; Laboratorio Oncología, Hospital Universitario Dexeus, Pangaea Oncology Lab, Barcelona, Spain.; Laboratorio Oncología, Germans Trias i Pujol Health Science Insitute and Hospital (IGTP), Badalona, Spain., Güerri-Fernandez R; Infectious Diseases Unit, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain., Gonzalez-Cao M; Instituto Oncologico Dr Rosell, Hospital Quiron-Dexeus Barcelona, Barcelona, Spain., Meyerhans A; Infection Biology Laboratory, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Catalan Institution for Research and Advanced Studies (ICREA) Pg. Lluiís Companys 23, Barcelona, Spain.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 Jul 05; Vol. 13, pp. 908108. Date of Electronic Publication: 2022 Jul 05 (Print Publication: 2022).
